This HTML5 document contains 217 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n11http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34172042
rdf:type
wikibase:Item
schema:description
vitskapeleg artikkel 2014年論文 mokslinis straipsnis bilimsel makale artigo científico (publicado na 2014) 2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած 2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված 2014年论文 2014 nî lūn-bûn научни чланак vitenskapelig artikkel บทความทางวิทยาศาสตร์ artigo científico 2014年論文 artículo científico publicado en 2014 научная статья سائنسی مضمون article científic 2014年论文 teaduslik artikkel 2014年論文 artigo científico (publicado na 2014) artikull shkencor tieteellinen artikkeli naučni članak ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2014年论文 2014年の論文 tudományos cikk vedecký článok 2014年論文 article scientifique (publié 2014) مقالهٔ علمی мақолаи илмӣ מאמר מדעי article scientific επιστημονικό άρθρο 2014年论文 articolo scientifico artículu científicu espublizáu en 2014 مقالة علمية wetenschappelijk artikel наукова стаття, опублікована у вересні 2014 videnskabelig artikel (udgivet 2014) სამეცნიერო სტატია 2014年论文 artykuł naukowy bài báo khoa học научни чланак научна статия scienca artikolo 2014年論文 scientific article artikulong pang-agham мақолаи илмӣ vetenskaplig artikel wissenschaftlicher Artikel 2014年论文 articol științific vědecký článek 2014년 논문
p:P577
wds:Q34172042-CD15BE11-3C72-4340-8641-0D58B6D7170C
wdt:P577
2014-09-01T00:00:00Z
p:P407
wds:Q34172042-572D4F25-15B0-4D3E-959A-215173E10AE0
wdt:P407
wd:Q1860
p:P2860
wds:Q34172042-0353339B-BD16-4FC4-AA4A-CFA1DBCC6C08 wds:Q34172042-04F4348C-B001-4B6D-B23C-EA02780DB678 wds:Q34172042-0F060FB6-AB88-4B8B-9646-AA4459D79957 wds:Q34172042-2660956F-1962-41DE-B380-03E52E10F1A1 wds:Q34172042-26B89F6F-13D1-4812-A529-93A48C5DEDCE wds:Q34172042-B9100D69-B370-4EF6-AF5B-5F45F74DD0D4 wds:Q34172042-BA63D3E8-1A60-4BB9-BF17-504ED023418E wds:Q34172042-C29FFD30-5627-4A46-AF21-0EF81D47FFA9 wds:Q34172042-C46BBB51-1ED6-45DA-9B8E-ABB9B6105776 wds:Q34172042-ABC4B332-377F-4735-BA39-B8E929DC58DB wds:Q34172042-B31DBD9F-D85E-41EF-9F81-DB1271C5E357 wds:Q34172042-CF65E538-BC96-4906-ADEE-E98DEE9B4B29 wds:Q34172042-D4481738-9D46-409F-A217-97237D99936B wds:Q34172042-DB3F0FAC-CC98-404D-B684-D815D291C728 wds:Q34172042-C64EB2D1-AE1E-42CF-A026-89E5DAB3732A wds:Q34172042-CBD26E32-5068-4D32-93CB-81CF12F1CB81 wds:Q34172042-7F81C089-27E2-4680-B3B4-33953B815B9E wds:Q34172042-80365771-8603-475D-9036-B41ED2D25364 wds:Q34172042-866FECFF-5EFB-4439-BB84-B7A9D69C3C38 wds:Q34172042-724E27C4-97E1-4A1A-964F-24062DC754C9 wds:Q34172042-738DA616-DA7E-4239-9201-5AE5E80D732F wds:Q34172042-9628B560-D96A-4099-A36C-AF9ED3676FAC wds:Q34172042-9A2D5502-810A-4488-806A-118E99E3039A wds:Q34172042-9CFF766B-997C-45E7-A790-9B1E2ABD0FA3 wds:Q34172042-A80DEDE7-EED4-47C4-8BBD-4A2EA8F7EA95 wds:Q34172042-9492ED58-457D-49FA-BDEF-C3466149B61D wds:Q34172042-95283B77-DC16-4327-A584-175407F5E4C8 wds:Q34172042-9583B750-A0F4-48C4-A7A4-7B49F2602F1A wds:Q34172042-F5BBF4A7-5399-4EB0-AF51-CFCB62250974 wds:Q34172042-F85CE5EA-BF44-4214-9996-FE4CA2F4D429 wds:Q34172042-FBE8A871-D1CF-4B87-8C91-CAC98C388B88 wds:Q34172042-DE25DB61-9B41-4EBA-9EB3-E743447B50D0 wds:Q34172042-EE7CD354-4105-4185-9B9B-33FEEEFA2FEA wds:Q34172042-F06E8EC0-3555-45F0-82DB-259F014571FB wds:Q34172042-411DD3AC-1915-49EE-8909-7BA287C58EAC wds:Q34172042-53569613-4246-4118-B665-1B2E50FB7FC2 wds:Q34172042-3DDD8BF4-1D0B-4ADB-AFF4-DE0E264C29B7 wds:Q34172042-5D503D49-C947-4798-8B6A-FCAFC50E01C7 wds:Q34172042-6CFF8A86-A1BE-4214-BA31-BF3DEDA70208 wds:Q34172042-5BFA70EC-D38D-4596-A30D-A548FCBB784E wds:Q34172042-0F3DE306-E3ED-4509-AB29-0A6AB2E0BCFA wds:Q34172042-1619FC24-2109-46FB-AA8D-E245F59DAD89
wdt:P2860
wd:Q34612121 wd:Q34612117 wd:Q28145831 wd:Q28203306 wd:Q35848876 wd:Q34742630 wd:Q50904360 wd:Q50923372 wd:Q27009160 wd:Q36058588 wd:Q33400617 wd:Q38068816 wd:Q34517403 wd:Q36928318 wd:Q40638371 wd:Q58481808 wd:Q71128005 wd:Q84567924 wd:Q77995358 wd:Q53358165 wd:Q28202341 wd:Q36407162 wd:Q78835139 wd:Q47929658 wd:Q44559233 wd:Q53446336 wd:Q37151698 wd:Q73335918 wd:Q43753300 wd:Q28202501 wd:Q44741042 wd:Q38469077 wd:Q46614351 wd:Q36022701 wd:Q36619678 wd:Q58481870 wd:Q33897659 wd:Q86202600 wd:Q54531264 wd:Q47791753 wd:Q28204295 wd:Q35909648
p:P2093
wds:Q34172042-EAA09A55-5062-4C2D-983B-4EFFC1475C70 wds:Q34172042-F7737035-4234-41A0-8AE2-DA14B1C0BD04 wds:Q34172042-6EDEA7F1-D8C0-4F8B-B86E-7D7B4AAC84D7 wds:Q34172042-91CB0857-C148-470E-B442-C75D265D0453 wds:Q34172042-171E552B-73A4-4BA3-9A42-CB253A121413 wds:Q34172042-1102DDE8-E17E-4FE2-B7CB-3EF8CB24A1A8 wds:Q34172042-1DD2D50B-97D5-45DA-8E44-3C15EE6A13C1 wds:Q34172042-24EEB134-00C5-40F7-91F5-7BAF85BE9899 wds:Q34172042-1761CC27-0A39-45D7-B0BD-42C69766375B wds:Q34172042-27457AC1-DC17-4B34-8E24-68A0C3313C66 wds:Q34172042-40BC8D48-0FBD-4D85-95AB-27C926D91D08 wds:Q34172042-596FADF0-4DC2-4D48-A74E-7620733F68FB wds:Q34172042-570CA0A9-E038-4A26-8AC3-C3868851C2CD wds:Q34172042-66DA65E2-1538-442F-BA69-47C27763CF6B
wdt:P2093
Todd A Alonzo Samir B Kahwash Susana C Raimondi Kathleen Glick Robert B Gerbing Alan S Gamis Lillian Sung Patti Byron Stella M Davies Soheil Meshinchi Richard Aplenc Laura Winter Betsy A Hirsch Franklin O Smith
rdfs:label
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
skos:prefLabel
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
schema:name
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
p:P50
wds:Q34172042-4DDB3ACF-00A0-43AE-9EC9-816D5BA9B5C0
wdt:P50
wd:Q59566725
p:P1476
wds:Q34172042-B6D2C242-DA6F-4350-B42F-67A4B28999B7
wdt:P1476
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
p:P304
wds:Q34172042-6CD9E56C-C5EA-4B50-AD96-A0CE0C91946C
wdt:P304
3021-3032
p:P31
wds:Q34172042-1C71F662-833B-47D8-83BC-8EA00EA2422E
wdt:P31
wd:Q13442814
p:P921
wds:Q34172042-D3FF3BC1-21BE-4BAE-9874-4697FF2297C6 wds:Q34172042-A8FFC87E-B532-4B18-9083-3F0FE8DEDD81 wds:Q34172042-831502EA-C47D-424C-A3A5-229D684DE78A wds:Q34172042-369E8AFE-FCC1-4616-8002-020CEB84C625
wdt:P921
wd:Q1492760 wd:Q42824827 wd:Q29496 wd:Q264118
p:P698
wds:Q34172042-2F834050-EB1E-4E33-973C-BB6AA0066BFA
wdtn:P698
n10:25092781
wdt:P698
25092781
p:P1433
wds:Q34172042-0ABAC576-6BD3-43F4-91DA-B15CDF462CE8
wdt:P1433
wd:Q400292
p:P433
wds:Q34172042-36B2014B-BCEA-485E-A11C-0B3DA3B493D2
p:P478
wds:Q34172042-378D4413-AEEF-4D9D-B3ED-4D8AC7D45B1E
wdt:P433
27
wdt:P478
32
p:P356
wds:Q34172042-C9F42839-A81C-46D5-B9B0-DAFE900FED8F
wdtn:P356
n11:JCO.2014.55.3628
wdt:P356
10.1200/JCO.2014.55.3628
p:P932
wds:Q34172042-7A6B6D5D-9FAD-4524-A37E-8E5B173BEF07
wdt:P932
4162498